BioXcel Therapeutics (BTAI) Enterprise Value (2017 - 2026)

BioXcel Therapeutics' Enterprise Value history runs 10 years deep, the most recent figure standing at -$17.2 million for Q1 2026.

• In Q1 2026, Enterprise Value rose 44.6% year-over-year to -$17.2 million; the TTM figure through Mar 2026 stood at -$17.2 million (up 44.6% YoY), while the FY2025 annual figure was -$28.8 million, up 3.67% from the prior year.
• Enterprise Value was -$17.2 million for Q1 2026 at BioXcel Therapeutics, up from -$28.8 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$17.2 million in Q1 2026 to a low of -$233.5 million in Q2 2022.
• Historically, Enterprise Value has averaged -$96.6 million across 5 years, with a median of -$65.2 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Enterprise Value decreased 3.31% in 2022, then surged 66.99% in 2025.
• A 5-year view of Enterprise Value shows it stood at -$193.7 million in 2022, then soared by 66.33% to -$65.2 million in 2023, then jumped by 54.23% to -$29.9 million in 2024, then increased by 3.67% to -$28.8 million in 2025, then soared by 40.26% to -$17.2 million in 2026.
• The last three Enterprise Value figures came in at -$17.2 million (Q1 2026), -$28.8 million (Q4 2025), and -$37.3 million (Q3 2025), per Business Quant data.